Beck Depression Inventory – Second Edition (BDI-II)

Abstract

The Beck Depression Inventory – Second Edition (BDI-II) is a 21-item self-report psychometric instrument designed to assess the presence and severity of depressive symptomatology in adults and adolescents aged 13 years and older. Developed by Aaron T. Beck, Robert A. Steer, and Gregory K. Brown in 1996, the BDI-II represents a major revision of the original Beck Depression Inventory (BDI; Beck et al., 1961) and its subsequent 1979 iteration (BDI-1A). The scale was recalibrated specifically to align depressive symptom criteria with the diagnostic framework established in the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Each item features four self-evaluative statements arranged in increasing order of clinical severity, scored on a 4-point Likert-type scale ranging from 0 to 3, yielding an overall composite score between 0 and 63. The temporal assessment window spans the preceding two weeks, capturing both chronic and acute depressive states.

Extensive psychometric investigations across international psychiatric, medical, and community samples indicate that the BDI-II possesses exceptional reliability and robust structural validity. Internal consistency estimates routinely achieve Cronbach’s coefficient alpha ($\alpha$) values of .92 to .93 among clinical psychiatric outpatients and .89 to .93 among non-clinical populations, with one-week test-retest reliability coefficients averaging $r = .93$. Structural equation modeling and exploratory/confirmatory factor analyses predominantly support an oblique two-factor framework consisting of a Cognitive-Affective dimension and a Somatic-Vegetative dimension, alongside higher-order general depression (bifactor) configurations. The inventory demonstrates strong convergent validity with clinician-administered instruments such as the Hamilton Depression Rating Scale (HAM-D) and the Montgomery-Åsberg Depression Rating Scale (MADRS), as well as parallel self-report tools including the Patient Health Questionnaire-9 (PHQ-9). With empirically grounded clinical cutoff scores delineating minimal (0–13), mild (14–19), moderate (20–28), and severe (29–63) depressive episodes, the BDI-II remains the gold standard self-report metric for treatment outcome monitoring, epidemiological screening, and clinical trials worldwide.

Keywords

Beck Depression Inventory-II, BDI-II, major depressive disorder, psychometrics, depression assessment, cognitive theory of depression, affective disorders, somatic-vegetative symptoms, internal consistency, construct validity, treatment outcome monitoring

Authors

The Beck Depression Inventory – Second Edition was developed through the collaborative clinical and psychometric research of three pioneering investigators in cognitive psychology and psychiatric assessment:

• Aaron T. Beck, M.D. — Late University Professor Emeritus of Psychiatry at the Perelman School of Medicine, University of Pennsylvania, and President Emeritus of the Beck Institute for Cognitive Behavior Therapy. Dr. Beck is widely celebrated as the father of Cognitive Therapy and Cognitive Behavioral Therapy (CBT).
• Robert A. Steer, Ed.D. — Professor of Psychiatry at the School of Osteopathic Medicine, Rowan University (formerly University of Medicine and Dentistry of New Jersey – UMDNJ), renowned for his extensive psychometric modeling of affective, cognitive, and substance abuse measurement scales.
• Gregory K. Brown, Ph.D. — Research Associate Professor of Clinical Psychology in Psychiatry at the Perelman School of Medicine, University of Pennsylvania, and Director of the Penn Center for the Prevention of Suicide, recognized for his work on suicide risk assessment, evidence-based psychotherapies, and depressive symptom quantification.

Institutional Origin: Center for Cognitive Therapy, Department of Psychiatry, University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States.

Purpose

The primary purpose of the Beck Depression Inventory – Second Edition is to quantify the severity of subjective depressive symptoms in clinical, psychiatric, medical, and research environments. It was engineered not as an autonomous categorical diagnostic instrument, but as a continuous severity metric designed to index the intensity of cognitive, affective, somatic, and vegetative manifestations of depression. Although clinician-administered interviews—such as the Structured Clinical Interview for DSM Disorders (SCID)—are mandatory for confirming formal nosological diagnoses of Major Depressive Disorder (MDD), Persistent Depressive Disorder (Dysthymia), or Bipolar Depression, the BDI-II provides an empirically validated, time-efficient medium for capturing the patient’s subjective psychological distress.

A central impetus for creating the BDI-II was the necessity to overhaul the 1979 BDI-1A to conform with the revised symptom profile of Major Depressive Episode detailed in the DSM-IV. The original BDI omitted critical diagnostic criteria, including psychomotor agitation, fatigue/loss of energy, feelings of worthlessness, and concentration impairment, while failing to detect atypical neurovegetative features such as hyperphagia (increased appetite) and hypersomnia (increased sleep). The BDI-II systematically incorporated these dimensions by removing obsolete items (such as body image change, work inhibition, and somatic preoccupation), adjusting the time frame from the past week to the past two weeks to mirror the DSM-IV minimum duration criterion, and introducing bidirectional response stems for vegetative alterations.

In clinical practice, the BDI-II serves several indispensable functions:

• Initial Clinical Triage: Assisting clinicians in outpatient, inpatient, and primary care settings in rapidly gauging symptom burden and identifying acute psychiatric crises, particularly through item 9, which evaluates suicidal thoughts or wishes.
• Measurement-Based Care: Facilitating longitudinal symptom tracking throughout psychotherapeutic interventions (e.g., Cognitive Behavioral Therapy, Interpersonal Psychotherapy) and psychopharmacological regimens (e.g., selective serotonin reuptake inhibitors [SSRIs]), allowing practitioners to determine therapeutic response, partial remission, full remission, or relapse.
• Clinical Research and Trials: Providing a standardized continuous endpoint for randomized controlled trials (RCTs) evaluating psychiatric, psychotherapeutic, neurostimulation (e.g., Transcranial Magnetic Stimulation, Electroconvulsive Therapy), and behavioral interventions.
• Medical Comorbidity Screening: Disentangling psychological depressive constructs from organic medical illness symptomatology across chronic health populations, including patients with cardiovascular disease, chronic pain, oncology conditions, human immunodeficiency virus (HIV), and neurological disorders.

Psychological Construct

The construct measured by the BDI-II is depressive symptom severity, conceptualized as a multi-tiered psychological and neurovegetative syndrome. Depression is characterized not by isolated low mood, but by an integrated constellation of cognitive distortions, affective blunting or dysregulation, behavioral inhibition, and vegetative alterations. The BDI-II systematically maps these facets into 21 discrete domains, broadly structured into cognitive-affective and somatic-vegetative dimensions:

Cognitive Dimension

The cognitive cluster of depressive symptoms reflects systematic negative biases in processing self-referential information. Within the BDI-II, this dimension is captured through several distinct variables:

• Pessimism (Item 2): Quantifies cognitive hopelessness, expectations of negative outcomes, and the perceived futility of personal agency regarding the future.
• Past Failure (Item 3): Captures retrospective autobiographical memory biases wherein the individual views their developmental and personal history as a cumulative sequence of deficits and failures.
• Guilty Feelings (Item 5): Measures excessive, inappropriate, or irrational self-reproach, moral culpability, and remorse over perceived transgressions.
• Punishment Feelings (Item 6): Reflects persecutory expectations, feelings of divine or systemic retribution, and beliefs that personal suffering is deserved.
• Self-Dislike (Item 7): Evaluates negative self-concept, profound self-disappointment, and emotional hostility directed inward against the self.
• Self-Criticalness (Item 8): Assesses cognitive schemas of self-blame, perfectionistic standards, and hyper-critical evaluation of personal performance and behavioral outcomes.
• Suicidal Thoughts or Wishes (Item 9): Measures the continuum of self-directed destructive ideation, ranging from passive death wishes to explicit suicidal intention.
• Indecisiveness (Item 13): Quantifies executive dysfunction, cognitive ambivalence, and an inability to select between competing behavioral choices.
• Worthlessness (Item 14): Captures profound global devaluation of one’s utility, social value, and existential worth compared to others.
• Concentration Difficulty (Item 19): Reflects subjective attentional deficits, cognitive slowing, and working memory distractibility.

Affective Dimension

The affective components evaluated by the instrument reflect profound alterations in mood, emotional reactivity, and hedonic capacity:

• Sadness (Item 1): Evaluates baseline dysphoria, subjective emotional pain, unyielding grief, and misery.
• Loss of Pleasure (Item 4): Assesses consummatory and anticipatory anhedonia, reflecting a loss of capacity to derive enjoyment or reward from previously reinforcing stimuli.
• Crying (Item 10): Measures affective lability, emotional tearfulness, or its extreme clinical manifestation—the inability to cry despite immense subjective distress.
• Agitation (Item 11): Captures inner tension, motor restlessness, psychomotor activation, and an inability to remain physically calm.
• Irritability (Item 17): Assesses reduced frustration tolerance, emotional reactivity, hypersensitivity to interpersonal annoyance, and anger outbursts.

Somatic-Vegetative Dimension

The somatic-vegetative cluster addresses the physiological, energetic, and homeostatic disruptions inherent to depressive pathology:

• Loss of Interest (Item 12): Reflects social withdrawal, interpersonal disengagement, and avolition toward environmental engagement.
• Loss of Energy (Item 15): Assesses physical anergy, systemic lethargy, and an absence of vitality required for basic functional tasks.
• Changes in Sleeping Pattern (Item 16): Evaluates bidirectional circadian dysregulation, accommodating insomnia (initial, middle, or terminal early morning awakening) as well as atypical hypersomnia.
• Changes in Appetite (Item 18): Indexes bidirectional metabolic and nutritional shifts, capturing both hypophagia (appetite suppression, weight loss) and hyperphagia (compulsive food craving, weight gain).
• Tiredness or Fatigue (Item 20): Quantifies physical exhaustion, somatic weariness, and excessive effort required to execute baseline activities.
• Loss of Interest in Sex (Item 21): Captures the erosion of libido, sexual apathy, and hypoactive sexual desire.

Theoretical Framework

The conceptual foundation of the BDI-II is anchored in Beck’s Cognitive Theory of Depression (Beck, 1967, 1976, 1987). Developed as an alternative to classical psychoanalytic and early drive-reduction models, Beck’s paradigm posits that depressive psychopathology is primarily driven, maintained, and exacerbated by dysfunctional cognitive structures rather than secondary affective shifts. According to this model, early adverse life events—such as chronic invalidation, trauma, neglect, or severe loss—foster latent negative core beliefs about the self, the external world, and the future.

The architecture of the theoretical framework comprises three interrelated structural levels:

1. The Negative Cognitive Triad: Depressed individuals operate under a systematic negative bias consisting of:
   • Negative View of the Self: The individual perceives themselves as intrinsically defective, unlovable, incompetent, and worthless (operationalized in BDI-II Items 3, 7, 8, and 14).
   • Negative View of the World/Experience: Environmental encounters are interpreted as fraught with unyielding demands, persistent obstacles, social rejection, and unavoidable failure (operationalized in Items 5, 6, and 12).
   • Negative View of the Future: Anticipation of unending suffering, chronic frustration, and inevitable failure, generating profound cognitive hopelessness (operationalized in Items 2 and 9).
2. Cognitive Schemas and Core Beliefs: Depressive schemas represent stable, enduring, stored knowledge representations formed during early development. While dormant during asymptomatic periods, these negative schemas are reactivated by stressful environmental life events that share structural or thematic features with the original sensitizing events (a classic diathesis-stress model). Once triggered, they bias information-processing networks, overriding realistic or balanced cognitive evaluations.
3. Cognitive Distortions (Systematic Processing Errors): As dormant schemas are activated, information processing is funneled through primitive, systematic cognitive errors. These include arbitrary inference (drawing conclusions without evidence), selective abstraction (focusing on an isolated negative detail while ignoring the broader context), overgeneralization (applying a single negative outcome to global self-worth), magnification and minimization (exaggerating faults while discounting achievements), and all-or-nothing (dichotomous) thinking.

The cognitive model dictates a reciprocal causal cascade: negative thoughts directly generate affective distress (sadness, guilt, emotional numbness), prompt somatic-vegetative dysregulation (fatigue, sleep disturbance, appetite changes), and inhibit adaptive behavioral activation (withdrawal, indecisiveness). The BDI-II was structured explicitly to reflect this interconnected schema, serving as an empirical mirror of Beck’s cognitive formulation of depressive illness.

Validity

The BDI-II has undergone comprehensive psychometric validation across thousands of empirical studies, establishing exceptional content, construct, convergent, discriminant, and criterion-related validity across heterogeneous clinical, psychiatric, medical, and community cohorts.

Content and Face Validity

Content validity was fortified during the instrument’s construction by directly mapping each item against the diagnostic criteria for a Major Depressive Episode listed in the DSM-IV. Beck, Steer, and Brown (1996) conducted extensive pilot evaluations with psychiatric panels and patients to verify that items exhaustively covered clinical manifestations while excluding redundant, somatic-bias items that contaminated earlier editions when administered to medically ill cohorts.

Convergent and Criterion Validity

The BDI-II demonstrates strong convergent correlations with clinician-rated depression indices and parallel self-report measures. In the original standardization sample by Beck et al. (1996), the BDI-II correlated strongly with the original BDI ($r = .93$) and the Hamilton Depression Rating Scale (HAM-D; $r = .71$) in psychiatric outpatients. Subsequent independent investigations have corroborated these associations:

• Montgomery-Åsberg Depression Rating Scale (MADRS): Correlations between the BDI-II and MADRS range from $r = .68$ to $.86$ across psychiatric clinical trials, demonstrating consistency between patient-reported severity and clinician ratings.
• Patient Health Questionnaire-9 (PHQ-9): Meta-analytic reviews report correlations between the BDI-II and the PHQ-9 exceeding $r = .80$ to $.85$, confirming equivalent construct measurement despite different structural formats.
• Center for Epidemiologic Studies Depression Scale (CES-D): Correlations between the BDI-II and CES-D in both university and geriatric populations range between $r = .75$ and $.84$.

Discriminant Validity

Discriminant validity has been demonstrated by evaluating the BDI-II against standardized anxiety, somatic, and personality inventories. Although depression and anxiety share substantial shared variance (reflecting general negative affectivity), the BDI-II correlates higher with alternative depression scales than with anxiety metrics. In clinical samples, correlations with the Beck Anxiety Inventory (BAI) typically range from $r = .50$ to $.60$, demonstrating acceptable divergence from somatic and panic anxiety states. Furthermore, studies evaluating the BDI-II against the State-Trait Anxiety Inventory (STAI) demonstrate that the BDI-II loads distinctively onto depressive factors rather than generalized autonomic arousal factors.

Predictive and Diagnostic Accuracy

Receiver Operating Characteristic (ROC) curve analyses establish that the BDI-II possesses high diagnostic sensitivity and specificity for detecting major depressive disorder as diagnosed by semi-structured clinical interviews (e.g., SCID). Using the standard cutoff score of $\ge 14$ for mild depression, sensitivity rates typically exceed 88% to 92%, with specificity ranging from 80% to 88% in outpatient settings. In screening for moderate-to-severe depression requiring intensive clinical stabilization, cutoffs of $\ge 20$ yield optimal trade-offs between false positives and false negatives, with areas under the curve (AUC) consistently ranging between .88 and .96 across clinical psychiatric research.

Reliability

The reliability of the BDI-II has been thoroughly demonstrated across classical test theory and item response theory (IRT) frameworks. The inventory exhibits robust internal consistency, stable temporal reproducibility, and high item-total test coherence across diverse demographic, geographic, and clinical groups.

Internal Consistency

In the initial normative psychometric evaluation published in the manual, Beck, Steer, and Brown (1996) reported a Cronbach’s alpha coefficient of $\alpha = .92$ for an outpatient psychiatric sample ($N = 500$) and $\alpha = .93$ for a sample of university undergraduate students ($N = 120$). Subsequent multi-center studies have confirmed these estimates:

• Psychiatric Inpatient Samples: Alpha coefficients consistently range from $\alpha = .91$ to $.95$, demonstrating that severe psychopathology and clinical distress do not undermine item coherence.
• Adolescent Samples: Among clinical adolescents aged 13–18 years, Steer et al. (1998) established an internal consistency of $\alpha = .91$.
• Medical and Geriatric Samples: Studies evaluating patients with medical illnesses (e.g., chronic kidney disease, post-myocardial infarction, multiple sclerosis) report internal consistency metrics between $\alpha = .88$ and $.92$.
• Cross-Cultural Translations: Validated adaptations worldwide—including German, French, Spanish, Japanese, Chinese, Arabic, and Persian versions—routinely yield alpha values exceeding .89, demonstrating that the psychometric integrity of the scale is preserved across languages.

Test-Retest Reliability

Temporal stability assessments demonstrate that the BDI-II reliably captures both the enduring trait-like severity of a depressive episode and short-term symptom fluctuations following clinical change:

• In the normative manual evaluation (Beck et al., 1996), a subsample of 26 psychiatric outpatients re-evaluated after a 1-week interval demonstrated a test-retest correlation coefficient of $r = .93$ ($p < .001$).
• Non-clinical samples evaluated over a 1- to 2-week retest window demonstrate test-retest correlations between $r = .85$ and $.90$.
• Over longer durations (e.g., several months), test-retest coefficients appropriately attenuate to $r = .60 – .70$, reflecting the naturalistic episodic remission or therapeutic resolution of depressive episodes.

Item-Total Correlations and Standard Error of Measurement

Corrected item-total correlations across the 21 items are uniformly positive and robust. In clinical samples, item-total correlations range from $r = .39$ (Item 21: Loss of Interest in Sex) to $r = .70$ (Item 4: Loss of Pleasure), with a median item-total correlation across studies around $r = .58$. The standard error of measurement (SEM) for the composite score is low (approximately 2.14 points for clinical outpatients), providing clinicians with a narrow confidence interval for calculating true scores and reliable change indices (RCI) during treatment monitoring.

Factor Analysis

The latent structural validity of the BDI-II has been investigated using Exploratory Factor Analysis (EFA), Confirmatory Factor Analysis (CFA), and multi-group structural equation modeling. Decades of structural research have elucidated the instrument’s factorial architecture across clinical and non-clinical populations.

Two-Factor Correlated Models

In the original factor analysis performed by Beck, Steer, and Brown (1996), principal axis factoring with promax (oblique) rotation was conducted separately on psychiatric outpatients and university college students. These analyses supported an oblique two-factor structural solution:

• Factor 1: Cognitive-Affective: This dimension accounts for the majority of the common variance and consists of items reflecting cognitive deprecation, affective distress, and pessimism (Sadness, Pessimism, Past Failure, Guilty Feelings, Punishment Feelings, Self-Dislike, Self-Criticalness, Suicidal Thoughts, Crying, Worthlessness).
• Factor 2: Somatic-Vegetative: This dimension reflects physical, neurovegetative, and psychomotor depletion (Loss of Pleasure, Agitation, Loss of Interest, Indecisiveness, Loss of Energy, Changes in Sleeping Pattern, Irritability, Changes in Appetite, Concentration Difficulty, Tiredness or Fatigue, Loss of Interest in Sex).

Notably, across collegiate non-clinical cohorts, Dozois, Dobson, and Ahnberg (1998) refined this structure, confirming that while the items group into two correlated dimensions, specific items (such as Loss of Pleasure and Indecisiveness) shift factor loadings depending on the clinical severity of the cohort, often loading more cleanly onto a pure Cognitive factor versus a combined Somatic-Affective factor.

Bifactor and Hierarchical Models

Modern psychometric investigations employing advanced CFA frequently find that a bifactor model provides the superior statistical fit to empirical data compared to first-order orthogonal or oblique models (Ward, 2006; Brouwer et al., 2013). In a bifactor specification:

• A single, overarching General Depression Factor directly influences all 21 items, capturing the common variance of generalized depressive pathology.
• Two distinct orthogonal group factors—Specific Cognitive and Specific Somatic-Vegetative—account for the unique sub-domain variance over and above the general factor.

Structural equation modeling studies evaluate model fit indices using standard contemporary criteria (e.g., Comparative Fit Index $[CFI] ge .95$, Tucker-Lewis Index $[TLI] ge .95$, Root Mean Square Error of Approximation $[RMSEA] le .05$, and Standardized Root Mean Square Residual $[SRMR] le .05$). Bifactor models routinely meet these strict statistical thresholds, affirming that while the BDI-II possesses multidimensional sub-components, summing all 21 items to yield a single composite score is psychometrically sound.

Instrument / Measurement Tool

The Beck Depression Inventory – Second Edition (BDI-II) is structured as follows:

• Test Type: Self-administered psychological rating scale; psychometric screening and severity inventory.
• Format: Paper-and-pencil questionnaire, computerized desktop assessment, or secure digital clinical platform.
• Number of Items: 21 items.
• Administration Time: Approximately 5 to 10 minutes (slightly longer for individuals with severe psychomotor slowing or severe cognitive impairment).
• Target Population: Adults and adolescents aged 13 years and older.
• Assessment Window: Past two weeks, including today.
• Response Scale: 4-point severity scale from 0 to 3 for each item, where higher scores reflect greater depressive symptom severity over the past two weeks.
• Bidirectional Vegetative Items:
  • Item 16 (Changes in Sleeping Pattern): Features seven response options to capture insomnia or hypersomnia (0, 1a, 1b, 2a, 2b, 3a, 3b), scored 0 to 3 based on severity.
  • Item 18 (Changes in Appetite): Features seven response options to capture decreased appetite or increased appetite (0, 1a, 1b, 2a, 2b, 3a, 3b), scored 0 to 3 based on severity.
• Scoring Mechanism: Calculated by summing the numerical ratings assigned to all 21 items. If a respondent selects multiple options within a single item, the option with the highest severity score is used for calculation. The total score ranges from 0 to 63.
• Standard Cutoff Classifications:
  • 0–13: Minimal depression (normal non-clinical variations in mood).
  • 14–19: Mild depression (clinically relevant symptoms that may warrant monitoring or brief intervention).
  • 20–28: Moderate depression (significant symptom burden typically warranting structured psychotherapeutic and/or psychopharmacological treatment).
  • 29–63: Severe depression (critical symptom intensity often requiring comprehensive psychiatric intervention, specialized outpatient care, or inpatient hospitalization).
• Critical Item Alert: Item 9 (Suicidal Thoughts or Wishes) requires immediate clinical review. Any non-zero response (score of 1, 2, or 3) necessitates a comprehensive clinical suicide risk assessment.

Permissions & Fee and Test Year

The Beck Depression Inventory – Second Edition was published in 1996 by The Psychological Corporation, which is now an imprint of Pearson Clinical Assessment. The instrument is a fully copyrighted, proprietary psychometric tool and is not in the public domain.

Administration requires the purchase of original scoring protocols, test forms, and the manual through Pearson Clinical Assessment or authorized international distributors. Users must meet clinical qualification requirements (Qualification Level B), which mandate graduate-level training in psychometrics, psychology, clinical medicine, psychiatry, or closely related mental health disciplines. Reproducing the complete testing forms, digital items, or scoring algorithms for publication, clinical distribution, or open-access research without a formal licensing agreement from Pearson is strictly prohibited under international copyright law.

References

• Beck, A. T. (1967). Depression: Clinical, experimental, and theoretical aspects. Harper & Row.
• Beck, A. T. (1976). Cognitive therapy and the emotional disorders. International Universities Press.
• Beck, A. T. (1987). Cognitive models of depression. Journal of Cognitive Psychotherapy, 1(1), 5–37.
• Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Manual for the Beck Depression Inventory–II. Psychological Corporation. https://doi.org/10.1037/t00742-000
• Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J. (1961). An inventory for measuring depression. Archives of General Psychiatry, 4(6), 561–571. https://doi.org/10.1001/archpsyc.1961.01710120031004
• Brouwer, D., Meijer, R. R., & Zevalkink, J. (2013). On the factor structure of the Beck Depression Inventory–II: Validation, calibration, and construct validity. Psychological Assessment, 25(2), 340–352. https://doi.org/10.1037/a0030932
• Dozois, D. J. A., Dobson, K. S., & Ahnberg, J. L. (1998). A psychometric evaluation of the Beck Depression Inventory–II. Psychological Assessment, 10(2), 83–89. https://doi.org/10.1037/1040-3590.10.2.83
• Steer, R. A., Kumar, G., Ranieri, W. F., & Beck, A. T. (1998). Use of the Beck Depression Inventory-II with depressed adolescent inpatients. Journal of Psychopathology and Behavioral Assessment, 20(3), 231–237. https://doi.org/10.1023/A:1023078411993
• Ward, L. C. (2006). Comparison of factor analytic models for the Beck Depression Inventory–II. Psychological Assessment, 18(1), 81–88. https://doi.org/10.1037/1040-3590.18.1.81

13. Items of the Scale (Questionnaire)